The purpose of this study is to evaluate antibody levels against Group B streptococcus in mothers and the risk of developing invasive Group B streptococcus disease in newborns of less than 6 days age as well as infants of age less than 90 days age.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Proportion (Percentage) of maternal subjects enrolled in the study relative to the number of pregnant women screened.
Timeframe: During routine antenatal visits in the 4 months enrollment period (in antenatal clinics attached to study delivery units or the clinics serving the population delivering at those unit)
Proportion (percentage) of maternal subjects enrolled in ante-natal clinics.
Timeframe: During routine antenatal visits in the 4 months enrollment period(in antenatal clinics attached to study delivery units)
Proportion (percentage) of maternal subjects enrolled at delivery.
Timeframe: At delivery
Proportion (percentage) of mother-infant dyads enrolled with data available to assess early censorship criteria.
Timeframe: At delivery
Proportion (percentage) of enrolled mother-infant dyads with cord blood collected.
Timeframe: At delivery
Proportion (percentage) of enrolled mother-infant dyads with both maternal and cord blood collected.
Timeframe: At delivery
Proportion (percentage) of mother-infant dyads with complete data on the defined key clinical variables.
Timeframe: Throughout the study, an average of 4 months.
Percentage of subjects who completed the 90-day follow up visit in subset of subjects eligible for this visit.
Timeframe: At 90 day follow up visit
Percentage of maternal subjects, with vaginal swab samples, culture positive for GBS.
Timeframe: Throughout the study, an average of 4 months.
Percentage of maternal subjects who had culture positive for GBS, classified by serotype.
Timeframe: Throughout the study, an average of 4 months.
GBS anti-capsular antibody concentration (serotype-specific anti capsular antibody) in maternal subjects, vaginally colonized with GBS.
Timeframe: At delivery
GBS anti-capsular antibody concentration (serotype-specific anticapsular antibody) in infant subjects.
Timeframe: At birth